莫西沙星与左氧氟沙星治疗慢性阻塞性肺病急性加重期疗效及安全性比较

Efficacy and Safety of Moxifloxacin and Levofloxacin in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

目的探讨莫西沙星与左氧氟沙星治疗慢性阻塞性肺病急性加重期疗效及安全性。方法方便选取2016年6月—2017年12月在该院治疗的106例慢性阻塞性肺病急性加重期患者随机分组,对照组患者应用左氧氟沙星治疗,实验组患者给予莫西沙星治疗,观察比较两组患者治疗效果和不良反应发生率差异。结果实验组患者总有效率92.46%明显高于对照组75.47%,差异有统计学意义(χ~2=6.095,P=0.013);实验组不良反应发生率9.43%较对照组22.64%明显降低,差异有统计学意义(χ~2=5.217,P=0.006)。结论针对慢性阻塞性肺病急性加重期患者给予莫西沙星治疗可提高治疗效果,降低不良反应发生率,疗效显著,安全性高,值得推广应用。

Objective To investigate the efficacy and safety of moxifloxacin and levofloxacin in the treatment of acute exacerbation of chronic obstructive pulmonary disease.Methods A total of 106 patients with acute exacerbation of chronic obstructive pulmonary disease who were convenient selected and treated in the hospital from June 2016 to December 2017 were randomized.The control group was treated with levofloxacin.The experimental group was treated with moxifloxacin.The difference in the patient's treatment effect and adverse reaction rate were observed.Results The total effective rate of the experimental group was 92.46%,which was significantly higher than that of the control group 75.47%,the different was statistically significant(χ^2=6.095,P=0.013).The incidence of adverse reactions in the experimental group was 9.43%,which was significantly lower than that of the control group(22.64%),the different was statistically significant(χ^2=5.217,P=0.006).Conclusion The treatment of moxifloxacin in patients with acute exacerbation of chronic obstructive pulmonary disease can improve the therapeutic effect,reduce the incidence of adverse reactions,and has obvious curative effect and high safety.It is worthy of popularization and application.